Origin Bio provides precision‑cut tumor slice platforms that preserve the native tumor microenvironment for ex‑vivo drug testing. The service delivers matched treated and untreated slices with multimodal molecular readouts and AI‑driven analytics to predict responses and identify biomarkers for oncology research.
Funding
Funding not disclosed
Founders
Product
Problem
Preclinical cancer research often relies on cell lines or organoids that lack the native tumor microenvironment, leading to limited predictive power for drug efficacy and biomarker discovery. Consequently, pharmaceutical developers face high failure rates when translating findings to human patients.
Solution
Origin Bio creates precision‑cut tumor slices (PCTS) from freshly resected patient tissue, preserving the original cellular composition, spatial architecture, and vasculature. These slices are divided into matched untreated and perturbed arms, enabling ex‑vivo testing of therapeutics such as checkpoint inhibitors, chemotherapies, and cytokines. After perturbation, the platform generates multimodal molecular readouts—including transcriptomics, proteomics, and histology—across multiple slices. Integrated AI models analyze the resulting datasets to predict drug response, identify biomarkers, and support hypothesis generation for oncology research. By providing a scalable, physiologically relevant testing pipeline, Origin Bio bridges the gap between in‑vitro models and clinical outcomes.
Target Audience
Primary customers are pharmaceutical and biotech companies conducting oncology drug discovery and development, as well as academic research labs seeking physiologically relevant tumor models for mechanistic studies.
Features
- Precision‑cut tumor slicing that retains intact microenvironment, cellular heterogeneity, and native vasculature
- Matched perturbation workflow allowing parallel untreated and drug‑treated conditions on the same patient sample
- Compatibility with a broad panel of therapeutic agents, including immune checkpoint inhibitors, chemotherapeutics, and cytokines
- Multimodal readout suite covering bulk transcriptomics, quantitative proteomics, and high‑resolution histological imaging
- AI‑driven analytics pipeline that integrates multimodal data to model drug response and discover predictive biomarkers
- Scalable format that supports high‑throughput testing across many patient samples and experimental conditions